<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004734</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS034447</org_study_id>
    <nct_id>NCT00004734</nct_id>
  </id_info>
  <brief_title>Vitamin Therapy for Prevention of Stroke</brief_title>
  <official_title>Vitamin Intervention for Stroke Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Neurological Disorders and Stroke (NINDS)</source>
  <brief_summary>
    <textblock>
      A stroke occurs when part of the brain is damaged from lack of normal blood supply. This may&#xD;
      result in difficulty with feeling, speech, muscle strength or coordination, movement,&#xD;
      thinking, or other brain functions. Having a stroke increases the risk of another stroke&#xD;
      occurring in the future. Higher blood levels of a natural chemical known as homocysteine may&#xD;
      contribute to hardening of the arteries in the brain or heart and increase the risk of stroke&#xD;
      or heart attack. Folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cyanocobalamin) may&#xD;
      lower blood levels of homocysteine and reduce the risk of having another stroke or a heart&#xD;
      attack.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of a second stroke in patients who have had a first stroke is between 7 and 10&#xD;
      percent per year. Myocardial infarction (heart attack) as a complication of stroke adds to&#xD;
      stroke death and disability. Because homocysteine may be a major contributor to stroke, its&#xD;
      reduction by appropriate intervention with vitamin supplements could reduce the impact of&#xD;
      recurrent stroke, myocardial infarction, and vascular death. The purpose of this trial is to&#xD;
      determine whether a multivitamin containing high-dose folic acid, pyridoxine, and&#xD;
      cyanocobalamin, in addition to best medical/surgical management and risk factor modification,&#xD;
      reduces the recurrence of stroke or occurrence of myocardial infarction in stroke patients&#xD;
      with elevated homocysteine levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1996</start_date>
  <completion_date>February 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Stroke</condition>
  <condition>Cerebral Infarction</condition>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pyridoxine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyanocobalamin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folic acid multivitamin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any stroke (non-disabling cerebral infarction, NDCI) &lt; 120 days prior to randomization&#xD;
&#xD;
          -  Symptoms lasting &gt; 24 hrs, or if &lt; 24 hrs, CT or MRI shows new infarction at expected&#xD;
             site&#xD;
&#xD;
          -  Modified Rankin score &lt; 3&#xD;
&#xD;
          -  Homocysteine level &gt; the 25th percentile, ie, 9.5 mol/L for men, and 8.5 mol/L for&#xD;
             women&#xD;
&#xD;
          -  Patient compliance with multivitamin during run-in phase &gt; 75%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stroke due to: intracranial hemorrhage, dissection of a cervico-cephalic artery,&#xD;
             veno-occlusive disease, drug abuse, vasculitis&#xD;
&#xD;
          -  CT or MRI shows lesion other than infarction as cause of syndrome&#xD;
&#xD;
          -  Modified Rankin score of 4 or 5 at eligibility&#xD;
&#xD;
          -  Presence of potential sources of cardiogenic emboli: atrial fibrillation, prosthetic&#xD;
             cardiac valve, intracardiac thrombus or neoplasm, valvular vegetation&#xD;
&#xD;
          -  Neurologic illness other than stroke that would prevent proper evaluation of recurrent&#xD;
             stroke&#xD;
&#xD;
          -  Illness that limits life expectancy to &lt; 2 years&#xD;
&#xD;
          -  Severe congestive heart failure&#xD;
&#xD;
          -  Renal insufficiency requiring dialysis&#xD;
&#xD;
          -  Untreated B12 deficiency or untreated pernicious anemia&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt;185 mm/Hg or diastolic &gt;105 mm/Hg on two readings&#xD;
             separated by 5 min.) at eligibility&#xD;
&#xD;
          -  Conditions preventing reliable participation in study: refractory depression, severe&#xD;
             cognitive impairment, alcoholism, other substance abuse&#xD;
&#xD;
          -  Medications given within last 30 days that affect homocysteine: methotrexate,&#xD;
             tamoxifen, L-dopa, phenytoin, or bile acid sequestrants that can decrease folate&#xD;
             levels&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Patients receiving active intervention in another trial&#xD;
&#xD;
          -  Patients on multi-vitamins, single B6, or folic acid, unless willing to discontinue&#xD;
             and take study supplement&#xD;
&#xD;
          -  Any surgical procedure, invasive cardiac instrumentation, endarterectomy, stent&#xD;
             placement, thrombectomy or other endovascular treatment of abnormal carotid artery&#xD;
             performed within 30 days prior to randomization or scheduled within 30 days after&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James F. Toole, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157-1068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>February 25, 2000</study_first_submitted>
  <study_first_submitted_qc>February 25, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>stroke</keyword>
  <keyword>cerebral infarction</keyword>
  <keyword>homocysteine</keyword>
  <keyword>vitamin</keyword>
  <keyword>folic acid</keyword>
  <keyword>pyridoxine</keyword>
  <keyword>vitamin B6</keyword>
  <keyword>cyanocobalamin</keyword>
  <keyword>vitamin B12</keyword>
  <keyword>multivitamin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

